U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H26N6O4S
Molecular Weight 506.5788
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAPRIZOSIN

SMILES

COc1cc2c(c(-c3ccccn3)c1OC)c(=N)[nH]c(n2)N4CCc5c(cccc5NS(=O)(=O)C)C4

InChI

InChIKey=OLYXPBZBZBVRGD-UHFFFAOYSA-N
InChI=1S/C25H26N6O4S/c1-34-20-13-19-22(21(23(20)35-2)18-8-4-5-11-27-18)24(26)29-25(28-19)31-12-10-16-15(14-31)7-6-9-17(16)30-36(3,32)33/h4-9,11,13,30H,10,12,14H2,1-3H3,(H2,26,28,29)

HIDE SMILES / InChI

Molecular Formula C25H26N6O4S
Molecular Weight 506.5788
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Taprizosin (also known as UK-338,003) is an alpha1A-adrenoceptor antagonist that was developed for the treatment of benign prostatic hyperplasia. However, this compound possesses poor oral absorption.

Approval Year

PubMed

PubMed

TitleDatePubMed
Investigation of regional mechanisms responsible for poor oral absorption in humans of a modified release preparation of the alpha-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): the rational use of ex vivo intestine to predict in vivo absorption.
2008 Jan
Substance Class Chemical
Created
by admin
on Sat Jun 26 06:34:40 UTC 2021
Edited
by admin
on Sat Jun 26 06:34:40 UTC 2021
Record UNII
EQ8YV2D86Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TAPRIZOSIN
INN  
INN  
Official Name English
TAPRIZOSIN [INN]
Common Name English
UK-338,003
Code English
UK-338003
Code English
Classification Tree Code System Code
NCI_THESAURUS C29713
Created by admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
NCI_THESAURUS C29707
Created by admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
Code System Code Type Description
FDA UNII
EQ8YV2D86Y
Created by admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
PRIMARY
EPA CompTox
210538-44-6
Created by admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
PRIMARY
CAS
210538-44-6
Created by admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
PRIMARY
ChEMBL
CHEMBL401796
Created by admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
PRIMARY
PUBCHEM
6433102
Created by admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
PRIMARY
INN
8286
Created by admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
PRIMARY
NCI_THESAURUS
C66580
Created by admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TRANSPORTER -> SUBSTRATE
WEAK
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

Tmax PHARMACOKINETIC ORAL ADMINISTRATION